This is not hype, legit deal with major partner - Up to 297 Million over five years, and no debt, seems like it's flying under the radar, should go higher in near term, but when earnings are announced it will definitely jump. The balance sheet doesn't lie!
10X average volume run on study enrollment, two analysts calls for $6-7$ Price targets, but rally fading on high volume,, discouraging. High short interest too, but can't see significant downside absent a negative clinical data release so you think there would be more covering since it's down 85% from its 52 week high! I have a feeling the market isn't attracting any buyers here until they show some promising data for the compounds in development? Anyone have any ideas when that will be?